39 results about "Mucosal tissue" patented technology

Modular mucosal tissue bioreactors combined with bioartificial mucus provide a high-fidelity, medium-throughput platform for evaluating CF treatments and modeling host-pathogen biology, a stepping stone towards better options for HEMT-nonresponsive patients. Whole lung ex vivo Cystic Fibrosis model system allows for investigation of candidate CF therapies.

The present invention provides a nutritional composition comprising one or more of vitamin D, polydextrose and galacto-oligosaccharides in combination with a calcium source. The composition has the effect of improving the intestinal mucosal barrier including improving intestinal mucosal permeability, modulating expression of intercellular tight junction proteins, improving intestinal mucosal tissue structure and improving levels of markers of the intestinal mucosal barrier.

This utility model relates to an orthodontic anchorage screw, which, from bottom to top, comprises a threaded section, a smooth section, a middle cap, a connecting rod section, and a top cap. The width of the connecting rod section is smaller than the width of the middle cap and the top cap at both ends. The middle cap, the connecting rod section, and the top cap form a groove for binding with a strap. The top cap is circular, with its top surface being an arched spherical surface with a smooth transition at the periphery, and its bottom surface also having a smooth transition at the periphery. The middle cap has a hexagonal prism-shaped portion. It is an orthodontic anchorage screw with a reasonable structure that reduces postoperative discomfort caused by friction between the intraoral anchorage screw and the mucosal tissue.

In some aspects, the disclosure relates to compositions and methods for skin repair and regeneration. In some embodiments, compositions described by the disclosure comprise natural products (e.g., extracts) combined with biotechnological excipient systems, such as bio surfactants, suitable for the repair of compromised skin, such as mucosal tissue (e.g., oral mucosal tissue).

The present disclosure relates to methods and compositions for local expression of IL-12 in mucosal tissues, preferably in combination with an IFN-1 activator / inducer, for use in cancer immunotherapy.SOLUTION: The present invention solves the unmet need in the art for effective local expression of IL-12 using derivatized chitosan polyplexes reversibly coated with polyanion-containing block copolymers for potent transfection of mucosal tissues present in or proximal to tumors.SELECTED DRAWING: Figure 6

The present invention relates to a non-human mammal model of HSV latent infection, which enables detection of HSV in mucosal tissue upon exposure to a stimulus that reactivates latent HSV within the body. The non-human mammal according to the present invention can contribute to elucidating the mechanism of HSV latent infection and reactivation in humans and to developing drugs and the like for HSV.

A method of treating a soft palate in a patient may involve advancing a tissue treatment portion of a soft palate treatment device through the patient's mouth, contacting a treatment surface of the tissue treatment portion with mucosal tissue of the soft palate, and delivering energy from the tissue treatment portion through the mucosal tissue to a target tissue in the soft palate beneath to the mucosal tissue, to change at least one property of the target tissue. The method may further involve cooling the mucosal tissue with a cooling member on the treatment surface of the tissue treatment portion and removing the tissue treatment portion from the mouth.

The invention relates to a nanoparticle for use as a drug carrier and the synthesis method of this nanoparticle. In the invention, magnesium / aluminium (Mg / AI) mucoadhesive thiolated layered double hydroxide (nLDHT) nanoparticles are thiolated with L-cysteine and / or thioglycolic acid and / or 2-iminothiolane hydrochloride and / or glutathione and / or N-acetyl cysteine and / or 3-mercaptopropionic acid and / or 6- mercaptohexanoic acid. Thus, nLDHT interacts with the mucin on the surface of the targeted mucosal tissue for a longer period of time and acts with fewer side effects in the target tissues.

In some aspects, the disclosure relates to compositions and methods for skin repair and regeneration. In some embodiments, compositions described by the disclosure comprise natural products (e.g., extracts) combined with biotechnological excipient systems, such as biosurfactants, suitable for the repair of compromised skin, such as mucosal tissue (e.g., oral mucosal tissue).

The present inventions provide improved solution compositions and methods for detecting cancerous and dysplastic lesions in mucosal tissue in vivo. Specifically, the disclosed pretreatment solution results in enhanced removal of mucous and tissue debris. The disclosed detection solution compositions (nuclear stain-based and lectin-based) provide enhanced disease detection, when used individually or sequentially, tissue permeation, fluorescent signal, and shelf stability. Lectin fragmentation methods and processes of manufacturing are also disclosed. Additionally, various methods utilizes the disclosed inventive solution compositions are disclosed for accurate disease detection in vivo yielding high sensitivity and specificity values.

The invention discloses an oral vaccine as well as a preparation method and application thereof, and relates to the technical field of pharmaceutical preparations. The oral vaccine comprises a core, and a permeation enhancing layer, an active molecular layer and an enteric coating layer which are sequentially coated on the surface of the core, the core is a biodegradable polymer nano particle; the permeation enhancing layer is a polydopamine layer loaded with a permeation enhancer; the active molecular layer is a chitosan layer loaded with an antigen and a targeting substance. The oral vaccine provided by the embodiment of the invention is good in stability, can ensure that the antigen is stable in gastrointestinal tracts and keeps activity, realizes targeted release of intestinal tracts, can activate far-end mucous membrane tissues at the same time, realizes broad-spectrum IgA and IgG immunization, and is suitable for delivery of various oral antigens.

The invention features a mucosal coating composition including: (i) water: (ii) at least one mucoadhesive polymer / polysaccharide (e.g., a concentration between 0.1-20% w / v); and (iii) at least one surfactant (e.g., a concentration between 0.005-5% w / v). Exhibit long-lasting residence times on mucosal tissues and prophylactic protection against transmucosal pathogens.

The nasal septum is reshaped by creating multiple holes in the cartilage. RF energy can be applied to ablate tissue around the holes in a manner that minimizes damage of surrounding epithelial and mucosal tissues.

Hydrolyzed collagen compositions are described that are used for treatment of impaired tissue including mucosal tissue or to prevent damage to healthy tissue. These compositions function to treat mucosal tissues found in the digestive, urinary, respiratory and reproductive systems. Oral or topical, site-specific delivery of the compositions may be via liquid, spray, gel, powder, tablet, capsule, or sheet form.

The invention belongs to the technical field of biological medicine and cell therapy, and particularly relates to a preparation method of a human-derived nasal mucosa mesenchymal stem cell medicine for treating sepsis, which comprises the following steps: cell separation: taking adult nasal mucosa tissues, cutting into pieces, digesting with 0.25% pancreatin, and terminating digestion with a DF12 culture medium containing 20% serum; primary culture: after the tissue adheres to the wall for one week by using the first-step culture medium, replacing a DF12 culture medium containing 10% of serum, and after the cells climb out of the tissue, centrifugally collecting the cells for primary culture; 3, primary culture: identifying a fourth generation of cell surface marker in primary culture by flow cytometry, the invention reveals the deep mechanism of function enhancement of HuNMSCs by inhibiting cell autophagy, maintaining the integrity of a cell membrane structure and improving the survival rate of a sepsis model through molecular means such as lipid metabonomics and the like for the first time, and the deep mechanism of function enhancement of the HuNMSCs is illustrated by using the HuNMSCs to inhibit cell autophagy, maintain the integrity of a cell membrane structure and improve the survival rate of the sepsis model. The possibility of treating sepsis by HuNMSCs is clarified, a brand new cell treatment strategy is provided for sepsis, and a foundation is laid for subsequent clinical application.

Provided are various formulations, which rapidly form into disulfide-linked hydrogels (e.g., PEG hydrogels) in 30 seconds or less. These rapidly forming hydrogels were also able to conform and adhere to mucosal tissues via PEG-mucin entanglements and hydrogen bonding. The crosslinked hydrogels are formed from disulfide exchange between a multivalent thiol component and a multivalent disulfide component. Also provided are methods of making and methods of using the crosslinked hydrogels.

This invention relates to the field of medical device technology and discloses an intestinal mucosal tissue oxygen saturation monitoring device, comprising a monitor body, a catheter, a balloon, a near-infrared spectral emission and detection device, a lead wire, an inflation tube, an inflation device, a partition, and tubing one and tubing two. This invention can be used to directly, objectively, and continuously assess changes in small intestinal mucosal microcirculation and tissue oxygen consumption, and can be applied in various clinical environments. Furthermore, it is based on jejunal catheter placement technology, a mature and technically simple technique that can be performed bedside and is suitable for use in primary hospitals and general wards.

A system for delivery of a therapeutic agent to a site in mucosal tissue is provided. The system includes a porous, mu- coadhesive polymeric matrix having a first and a second opposed surfaces. The matrix is formed by a composition including chitosan, a hydration promoter, a microparticle adhesion inhibitor, and a microparticle aggregation inhibitor. A plurality of micro- particles are embedded within the matrix. The microparticles contain a therapeutic agent and have a coating around the therapeutic agent. The first surface of the matrix is configured to be attached to the site in the mucosal tissue and the matrix is configured to provide controlled release of the microparticles through the first surface. The coating of the microparticles includes chitosan so as to provide controlled release of the agent from the microparticles.

A system is disclosed for delivery of a therapeutic agent to a site in mucosal tissue or to the skin of a patient. The system includes a porous mucoadhesive, freeze-dried matrix formed by a composition including chitosan in an aqueous salt solution of a chloride salt of a monovalent cation. The system further includes a plurality of chitosan microparticles having an average diameter between 500 nm and 2000 nm and comprising a therapeutic agent.

The present application belongs to the technical field of nutritional health food, and particularly relates to a composition for repairing oral mucosa and a preparation method and application thereof. The composition comprises, by weight of the composition: 2%-80% of yeast beta glucan, 0.5%-50% of lactobacillus salivarius powder, 0.5%-50% of lactobacillus acidophilus powder, and 0.5%-50% of paracasei lactobacillus powder. The composition for repairing oral mucosa and the auxiliary materials are further prepared into a functional food in the form of tablets, liquids, soft candies or powders. In the functional food, the composition as the main component plays a role in repairing and preventing damage to the oral mucosa. Meanwhile, the composition and the auxiliary materials are dissolved under the action of oral saliva enzymes, thereby fully contacting the oral mucosa and pathogens and emitting a sweet and sour taste, so as to bring a pleasant sensory experience to the oral cavity.

The utility model discloses a mucous membrane tissue low-temperature plasma incision knife under an endoscope, which belongs to the technical field of operation electrodes and comprises a working knife head which comprises a first knife head and a second knife head. The first tool bit is used for dotting and marking, and the second tool bit is used for cutting mucous membrane tissues; the second tool bit is a rhombic double-edge tool bit, a ceramic insulating coating is arranged on the surface of the second tool bit, and the cutting edge position of the second tool bit is not coated with the ceramic insulating coating; and the working tool bit is connected with the handle through the flexible pipe group. The problems that electrodes need to be replaced in an operation and a large amount of harmful smoke is generated in the cutting process are solved.

Hydrolyzed collagen compositions are described that are used for treatment of impaired tissue including mucosal tissue or to prevent damage to healthy tissue. These compositions function to treat mucosal tissues found in the digestive, urinary, respiratory and reproductive systems. Oral or topical, site-specific delivery of the compositions may be via liquid, spray, gel, powder, tablet, capsule, or sheet form.

Disclosed is a cryogenic catheter probe, cryogenic ablation system, and use thereof for performing cryogenic ablation of mucosal tissue and / or of both mucosal tissue and submucosal tissue in the gastrointestinal tract of a subject. The cryogenic catheter probe includes a chamber and a channel assembly housed within the chamber. The channel assembly includes a central rail, at least one cryogenic fluid delivery channel, a delivery channel guide, and a sprayer guide. The at least one cryogenic fluid delivery channel has a fluid delivery channel portion and a sprayer connected to the fluid delivery channel portion, and is mounted on the central rail for longitudinal movement along the central rail. The sprayer is configured to release cryogenic spray in at least one treatment zone along the hollow body portion of the chamber.

The invention provides a gear autorotation clamp driving suture device. The gear autorotation clamp driving suture device comprises a mounting shell, an arc suture needle, a guide frame, a rotation control piece and a clamping assembly. The rotating control piece and the clamping assembly are arranged in the direction of the rotating axis of the arc-shaped suture needle, and in the arrangement mode, in the radial direction of the circle where the arc-shaped suture hole is located, the rotating control piece and the clamping assembly are not overlapped with the suture groove, so that the rotating control piece and the clamping assembly are prevented from interfering with human mucosal tissue entering the suture groove; the suture groove can contain more human mucosa tissues, so that the arc-shaped suture needle can effectively suture the human mucosa tissues; besides, the clamping locking piece can be fixed at any position of the arc-shaped suture needle, so that the arc-shaped suture needle can be driven to rotate at any angle, and the precision requirement of matching between the clamping locking piece and the arc-shaped suture needle is greatly reduced; in this way, the situation that the device loses efficacy due to the fact that the matching precision between the clamping locking piece and the arc-shaped suture needle is not enough is avoided.

This invention discloses a high-resolution, wide-field-of-view molecular fluorescence endoscopy system for the intestine. It employs the principle of wide-field fluorescence imaging, using a dual-wavelength semiconductor continuous laser as the excitation source, coupled with a high-resolution flexible imaging fiber bundle and microlens group. Fluorescence signal detection is achieved through a dichroic mirror, filters, and a cooled EMCCD. The system can acquire images of the microstructure and specific molecular distribution of intestinal mucosal tissue with a wide field of view and high resolution. It can rapidly achieve intestinal lesion screening, in-situ pathological staging, and minimally invasive treatment evaluation, completing real-time in vivo fluorescence imaging and pathological diagnosis of the intestine. It is suitable for rapid screening of lesion sites, in-situ diagnostic staging, and minimally invasive treatment evaluation in the intestinal system.

This application discloses a method and related apparatus for processing electronic gastrointestinal endoscope images. The method includes determining the grayscale distribution data corresponding to the R-channel image; selecting several target grayscale levels based on the grayscale distribution data; calculating the gain coefficient corresponding to the endoscope image based on the several target grayscale levels; and performing gain merging on the R-channel image, G-channel image, and B-channel image based on the gain coefficient to obtain the processed endoscope image. This application determines the gain coefficient through the R-channel image and adjusts the images of each channel based on the gain coefficient. Due to the absorption and scattering characteristics of blood vessels and mucosal tissues in the human digestive tract to cold light illumination, the absorption capacity of mucosa and blood vessels for red light is relatively weaker than that for green and blue light. Therefore, the R-channel image in the endoscope image has a higher intensity than the G-channel and B-channel images. Thus, determining the gain coefficient based on the R-channel image to adjust the endoscope image can improve the image quality of the adjusted endoscope image.

The presently disclosed subject matter provides for decellularized extracellular matrix (dECM) compositions for reconstructing mucosal tissue of trachea and methods of using the same. In certain embodiments, the composition can be a pre-gel containing dECM derived from tracheal mucosal tissue; a hydrogel obtained by gelling the pre-gel; or a vitrified membrane obtained by drying the hydrogel.

This determination device comprises a processor that acquires a Raman spectrum which has been detected by irradiating a gastrointestinal mucosal tissue with excitation light having a prescribed wavelength, that calculates, from the Raman spectrum in a first wavenumber band, a first feature amount which represents the state or amount of a substance contained in the mucosal epithelium, that determines the risk of future deterioration of the gastrointestinal mucosal tissue on the basis of the first feature amount, and that outputs the result of the determination. Thus, provided is a determination device which is capable of accurately determining the risk of future deterioration of a gastrointestinal mucosal tissue.

The invention is suitable for the technical field of biological medicines and gynecological external preparations, and provides a temperature-sensitive gynecological gel for preventing vaginal mucosa atrophy and a preparation method thereof. The gynecological gel is prepared from the following raw materials in parts by weight: 70 to 95 parts of temperature-sensitive gel matrix, 1 to 5 parts of prebiotics, 0.01 to 0.1 part of superoxide dismutase, 1 to 3 parts of modified glycyrrhizic acid and 2 to 4 parts of sustained release microspheres of which the internal effective component is tanshinone IIA (at) collagen-sodium hyaluronate, the anti-inflammatory and anti-oxidation effects of the modified glycyrrhizic acid, the safe microcirculation improvement effect of the tanshinone IIA and the moisturizing, mucous membrane tissue repair promotion and anti-inflammatory effects of the collagen and the sodium hyaluronate have a synergistic effect, so that the vaginal atrophic mucous membrane is efficiently repaired; the invention also discloses a preparation method of the temperature-sensitive gel. The gel preparation is stable in preparation process and high in safety, is suitable for preventing and treating vaginal mucosa atrophy caused by postmenopausal or hormone level fluctuation, and has a good clinical application prospect.

This provides a method for administering diazepam in a multimodal delivery profile. [Solution] A method is provided for administering diazepam in a multimodal delivery profile, which includes delivering diazepam from a matrix and facilitating the permeation of at least some of the diazepam through mucosal tissue.